Non-small cell lung cancer(NSCLC)
Conditions
Interventions
Gold Standard:Clinical trials verifying the consistency of AmoyDx Essential NGS Panel (Reversible Terminator Sequencing)
Index test:the 
detection 
of 
EGFR/ALK/ROS1/RET/KRAS/NRAS/PIK3CA/BRAF/HER2/MET 
gene 
in 
human(Reversible 
Sequencing) 
Sponsors
Beijing Chest Hospital affiliated to Capital Medical University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Patients with diagnosed non-small cell lung cancer; 2. The age of the subjects is >=18 years old; the gender is not limited; 3. Sufficient tissue samples can be provided to meet the research requirements: 8~10 slices with a thickness of 5µm; 4. The tumor cell content in the tissue specimen should be >=20%; 5. The sample storage period shall not exceed 18 months.
Exclusion criteria
Exclusion criteria: 1. Samples with incomplete or untraceable traceability information; 2. Other situations that the investigator considers unsuitable to participate in this clinical study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| gene mutation; | — |
Countries
China
Contacts
Public ContactChe Nanying
Beijing Chest Hospital affiliated to Capital Medical University
Outcome results
None listed